SCHEMBL5344161

SCHEMBL5344161

O=C1COc2ncc(C=C3SC(=S)NC3=O)cc2N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.48
CSNK2A2 P19784 3/20 0.47
CLK1 P49759 3/20 0.47
CSNK2B P67870 3/20 0.47
CSNK2A1 P68400 3/20 0.47
DYRK1A Q13627 3/20 0.47
DYRK2 Q92630 3/20 0.47
DYRK1B Q9Y463 3/20 0.47
PIK3CD O00329 2/20 0.47
PIK3CA P42336 2/20 0.47
PIK3CG P48736 2/20 0.47
HASPIN Q8TF76 2/20 0.47
CLK4 Q9HAZ1 2/20 0.47
PRKCB P05771 1/20 0.47
NAT1 P18440 5/20 0.47
CISD1 Q9NZ45 2/20 0.47
MAOA P21397 1/20 0.47
PIM1 P11309 1/20 0.46
CLK3 P49761 1/20 0.46
MYLK2 Q9H1R3 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5344157 1.00 DNM1 (0.48) DNM1CSNK2A2CLK1CSNK2BCSNK2A1
SCHEMBL5342147 0.78 CSNK2A2 (0.61) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL5342146 0.78 CSNK2A2 (0.61) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A
SCHEMBL5336100 0.77 DNM1 (0.59) DNM1CSNK2A2CLK1CSNK2BCSNK2A1
SCHEMBL5336102 0.77 DNM1 (0.59) DNM1CSNK2A2CLK1CSNK2BCSNK2A1
SCHEMBL2796664 0.76 NR3C2 (0.41) ALDH1A1LMNAMAPTKMT2A
SCHEMBL5341980 0.76 DNM1 (0.51) DNM1CSNK2A2CLK1CSNK2BCSNK2A1
SCHEMBL5341982 0.76 DNM1 (0.51) DNM1CSNK2A2CLK1CSNK2BCSNK2A1
SCHEMBL5396619 0.76 MEN1 (0.60) DNM1CSNK2A2CLK1CSNK2BCSNK2A1
SCHEMBL5340064 0.74 PDE4B (0.63) CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7205295-B2 Benzoxazin-3-ones and derivatives thereof as therapeutic agents WARNER-LAMBERT COMPANY LLC (US) 2007-04-17 US disclosed
EP-1569653-A1 BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K Warner-Lambert Company LLC (US) 2005-09-07 EP disclosed
WO-2004052373-A1 BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K WARNER-LAMBERT COMPANY LLC (US) 2004-06-24 WO disclosed
US-20040121996-A1 Benzoxazin-3-ones and derivatives thereof as therapeutic agents BARVIAN NICOLE (US) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121996-A1 Benzoxazin-3-ones and derivatives thereof as therapeutic agents XDH, HAX1, CYP4X1 DNM1 4688/4885CSNK2A2 1028/4885CLK1 1382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.